Loading...
SAT-477 Melanoma Treated with Pembrolizumab Leading to Thyroiditis and Subsequent Hypothyroidism
Background: Pembrolizumab (PD-1) is an immune checkpoint inhibitor used for treating melanoma and has been associated endocrine immune-related adverse events. Case Presentation: 76-year-old Caucasian male presented for evaluation of abnormal thyroid labs. Significant co-morbidities included recurren...
Na minha lista:
| Udgivet i: | J Endocr Soc |
|---|---|
| Hovedforfatter: | |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Oxford University Press
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7208300/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.983 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|